We propose that a tumor‐specific, MYCN‐targeted siRNA (siMYCN) treatment for disseminated neuroblastoma may be achieved by systemic administration of the siRNA encapsulated in a suitable nanoparticle formulation. Here, MYCN is linked to neuroblastoma.